Results 21 to 30 of about 3,401,781 (173)
Lost in translation: why cytokine release syndrome reporting fails clinical trials [PDF]
Cytokine release syndrome (CRS) is among the most frequently reported adverse events in trials of immune-cell-engaging therapies, yet its identification, grading, and reporting remain inconsistent across sponsors and investigators, driving overly ...
Stephane Champiat
doaj +2 more sources
Rituximab and Cytokine Release Syndrome [PDF]
Rituximab is a biologic agent that is usually well tolerated. With its increasing use for a myriad of rheumatologic and immunologic conditions, post-marketing surveillance has revealed more side effects. Systemic inflammatory response syndrome associated
Hrishikesh S. Kulkarni +1 more
doaj +2 more sources
Cytokine Release Syndrome: An Overview on its Features and Management
Cytokine release syndrome (CRS) is a life threatening toxicity associated numerous immunotherapeutic techniques involving monoclonal antibodies, bispecific antibodies and adoptive T cell therapies. It is also referred as infusion reaction that results in
Shailza Shreshtha +3 more
doaj +2 more sources
Targeting the A3 adenosine receptor to treat cytokine release syndrome in cancer immunotherapy
Shira Cohen, Pnina FishmanCan-Fite BioPharma Ltd., Kiryat-Matalon, Petah-Tikva 49170, IsraelAbstract: Cancer patients undergoing immunotherapy may develop cytokine release syndrome (CRS), an inflammatory cytokine storm condition, followed by neurotoxic ...
Cohen S, Fishman P
doaj +1 more source
Cytokine release syndrome: grading, modeling, and new therapy
Genetically modified T cells that express a chimeric antigen receptor (CAR) are opening a new frontier in cancer immunotherapy. CAR T cells currently are in clinical trials for many cancer types.
Delong Liu, Juanjuan Zhao
doaj +2 more sources
Immune checkpoint inhibitors have dramatically improved the prognosis of NSCLC. However, various immune-related adverse events (irAEs) have been reported. Cytokine release syndrome (CRS) is an irAE that is occasionally severe and life-threatening. CRS is
Ken Yamamoto, MD +3 more
doaj +2 more sources
Multimodality Imaging of Acute Myocarditis in Cytokine Release Syndrome (CRS) Following CAR-T Therapy. [PDF]
Maheswaran J +4 more
europepmc +3 more sources
Stephanie Si,1,2 David T Teachey1,2 1Children’s Hospital of Philadelphia, Division of Oncology, Philadelphia, PA, USA; 2Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USACorrespondence: Stephanie
Si S, Teachey DT
doaj +1 more source
Hemophagocytic lymphohistiocytosis/cytokine release syndrome secondary to neoadjuvant pembrolizumab for triple-negative breast cancer: a case study [PDF]
As indications for immune checkpoint inhibitors for breast cancer continue to expand, rare toxicities will emerge that require careful consideration and multidisciplinary management.
Laura Patton +5 more
doaj +2 more sources
Cytokine release syndrome (CRS) can be induced by immune checkpoint inhibitors (ICIs). Although the incidence of CRS is low, it is often underreported.
Yujing Zhang +6 more
doaj +2 more sources

